ABSTRACT

Melanoma is a type of cancer with a relatively poor prognosis. The development of immunotherapy for the treatment of patients with melanoma has drawn considerable attention in recent years. It is of great clinical significance to identify novel promising prognostic biomarkers and to explore their roles in the immune microenvironment. The solute carrier (SLC) superfamily is a group of transporters predominantly expressed on the cell membrane and are involved in substance transport. SLC16A1 is a member of the SLC family, participating in the transport of lactate, pyruvate, amino acids, ketone bodies, etc. The role of SLC16A1 in tumor immunity has been recently elucidated, while its role in melanoma remains unclear. In this study, bioinformatics analysis was performed to explore the role of SLC16A1 in melanoma. The results showed that high SLC16A1 expression was correlated with decreased overall survival in patients with melanoma. The genes co-expressed with SLC16A1 were significantly enriched in metabolic regulation, protein ubiquitination, and substance localization. Moreover, SLC16A1 was correlated with the infiltration of immune cells. In conclusion, SLC16A1 is a robust prognostic biomarker for melanoma and may be used as a novel target in immunotherapy.

摘要

黑色素瘤是一种预后相对较差的癌症。近年来，用于治疗黑色素瘤患者的免疫疗法的发展引起了相当大的关注。识别新的有前景的预后生物标志物并探索它们在免疫微环境中的作用具有重要的临床意义。溶质载体 (SLC) 超家族是一组主要在细胞膜上表达并参与物质转运的转运蛋白。SLC16A1是SLC家族的一员，参与乳酸、丙酮酸、氨基酸、酮体等的转运。SLC16A1在肿瘤免疫中的作用最近被阐明，但其在黑色素瘤中的作用尚不清楚。在这项研究中，进行了生物信息学分析以探索 SLC16A1 在黑色素瘤中的作用。结果表明，SLC16A1 的高表达与黑色素瘤患者的总体生存率降低相关。与 SLC16A1 共表达的基因在代谢调控、蛋白质泛素化和物质定位方面显着丰富。此外，SLC16A1 与免疫细胞的浸润相关。总之，SLC16A1 是一种强有力的黑色素瘤预后生物标志物，可用作免疫治疗的新靶点。